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6 versus 12 months of adjuvant trastuzumab for 
HER2-positive early breast cancer (PERSEPHONE): 4-year 
disease-free survival results of a randomised phase 3 
non-inferiority trial
Helena M Earl, Louise Hiller, Anne-Laure Vallier, Shrushma Loi, Karen McAdam, Luke Hughes-Davies, Adrian N Harnett, Mei-Lin Ah-See, 
Richard Simcock, Daniel Rea, Sanjay Raj, Pamela Woodings, Mark Harries, Donna Howe, Kerry Raynes, Helen B Higgins, Maggie Wilcox, 
Chris Plummer, Janine Mansi, Ioannis Gounaris, Betania Mahler–Araujo, Elena Provenzano, Anita Chhabra, Jean E Abraham, 
Carlos Caldas, Peter S Hall, Christopher McCabe, Claire Hulme, David Miles, Andrew M Wardley, David A Cameron, Janet A Dunn on behalf of 
PERSEPHONE Steering Committee and Trial Investigators*
Summary
Background Adjuvant trastuzumab significantly improves outcomes for patients with HER2-positive early breast 
cancer. The standard treatment duration is 12 months but shorter treatment could provide similar efficacy while 
reducing toxicities and cost. We aimed to investigate whether 6-month adjuvant trastuzumab treatment is non-
inferior to the standard 12-month treatment regarding disease-free survival.
Methods This study is an open-label, randomised phase 3 non-inferiority trial. Patients were recruited from 152 centres 
in the UK. We randomly assigned patients with HER2-positive early breast cancer, aged 18 years or older, and with a 
clear indication for chemotherapy, by a computerised minimisation process (1:1), to receive either 6-month or 
12-month trastuzumab delivered every 3 weeks intravenously (loading dose of 8 mg/kg followed by maintenance 
doses of 6 mg/kg) or subcutaneously (600 mg), given in combination with chemotherapy (concurrently or 
sequentially). The primary endpoint was disease-free survival, analysed by intention to treat, with a non-inferiority 
margin of 3% for 4-year disease-free survival. Safety was analysed in all patients who received trastuzumab. This 
trial is registered with EudraCT (number 2006–007018–39), ISRCTN (number 52968807), and ClinicalTrials.gov 
(number NCT00712140).
Findings Between Oct 4, 2007, and July 31, 2015, 2045 patients were assigned to 12-month trastuzumab treatment 
and 2044 to 6-month treatment (one patient was excluded because they were double randomised). Median follow-up 
was 5·4 years (IQR 3·6–6·7) for both treatment groups, during which a disease-free survival event occurred in 
265 (13%) of 2043 patients in the 6-month group and 247 (12%) of 2045 patients in the 12-month group. 4-year 
disease-free survival was 89·4% (95% CI 87·9–90·7) in the 6-month group and 89·8% (88·3–91·1) in the 12-month 
group (hazard ratio 1·07 [90% CI 0·93–1·24], non-inferiority p=0·011), showing non-inferiority of the 6-month 
treatment. 6-month trastuzumab treatment resulted in fewer patients reporting severe adverse events (373 [19%] of 
1939 patients vs 459 [24%] of 1894 patients, p=0·0002) or stopping early because of cardiotoxicity (61 [3%] of 
1939 patients vs 146 [8%] of 1894 patients, p<0·0001).
Interpretation We have shown that 6-month trastuzumab treatment is non-inferior to 12-month treatment in patients 
with HER2-positive early breast cancer, with less cardiotoxicity and fewer severe adverse events. These results 
support consideration of reduced duration trastuzumab for women at similar risk of recurrence as to those included 
in the trial.
Funding UK National Institute for Health Research, Health Technology Assessment Programme.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Trastuzumab delivered with chemotherapy for patients 
with HER2-positive breast cancer in the metastatic1 
and adjuvant settings2–4 resulted in improved treatment 
outcomes, and long-term follow-up has confirmed these 
benefits.5,6 A 12-month treatment duration with adjuvant 
trastuzumab was chosen arbitrarily for the pivotal 
licensing trials2–4 and, subse quently, became standard. 
However, results from the FinHer trial,7 which randomly 
assigned patients to adjuvant chemotherapy with or 
without 9 weeks of concurrent trastuzumab, showed 
a statistically sig nificant improvement in disease-free 
survival for patients assigned to trastuzumab (hazard ratio 
[HR] 0·29 [95% CI 0·13–0·64; p=0·002) and generated 
considerable interest in the possibility of shorter trastu-
zumab durations than the standard treatment time. 
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Trastuzumab has well recog nised toxic effects, particularly 
cardiac,8–11 and substantial costs. Studies have been done 
to assess whether similar outcomes can be achieved 
with reduced treatment duration. PHARE (France),12 
PERSEPHONE (UK),13 and the HORG study (Greece)14 
compared 6-month with 12-month trastuzumab treat-
ments. Short-HER (Italy)15 and SOLD (international)16 
compared treatment for 12 months with treatment for 
9 weeks (concurrently with docetaxel-first sequenced 
chemotherapy), and E219817 compared treatment for 
12 months with 12-week treatments (concurrently with 
weekly paclitaxel). Five of these six de-escalation trials 
were supported wholly or in part by government funding 
and aimed to discover the optimal balance between 
efficacy, toxicity, and cost for patients and health services. 
The PERSEPHONE trial, reported in this Article, aimed 
to investigate the hypothesis that 6-month adjuvant 
trastuzumab treatment is non-inferior to the standard 
12-month treatment in terms of outcomes, but with 
reduced toxicity. The trial uses a non-inferiority design18 
and we report 4-year disease-free survival results, the 
definitive primary endpoint.
Methods
Study design
PERSEPHONE was a prospective, multicentre, phase 3 
randomised trial to test the hypothesis that 6 months 
of trastuzumab treatment is non-inferior to the stan-
dard 12-month treatment. Patients were recruited in 
152 hospitals in the UK. The trial was approved by 
the Multi-Centre Research Ethics Committee (MREC) on 
Aug 9, 2007, (07/MRE08/35), and then by Research 
and Development departments at each participating 
institu tion. It was sponsored by Cambridge University 
Hospital National Health Service Trust and University 
of Cambridge; and co-ordinated and analysed by the 
Warwick Clinical Trials Unit at the University of 
Warwick. The trial was done in accordance with the 
Declaration of Helsinki and supported by the National 
Cancer Research Network (number 4078), which funded 
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Research in context
Evidence before this study
We searched PubMed in October, 2006, using search terms 
“trastuzumab”, “adjuvant”, and “HER2 positive breast cancer”, 
for papers published in English. We found three randomised 
controlled trials of adjuvant trastuzumab added to 
chemotherapy versus chemotherapy alone for patients with 
HER2-positive early breast cancer. In 2005, two reports 
established 12-month trastuzumab as the standard of care. 
The HERA trial examined both 24-month and 12-month 
trastuzumab compared with a no trastuzumab control group 
and reported a benefit of disease-free survival at 2 years of 
8·4% (95% CI 2·1–14·8) for the 12-month treatment group 
compared with the no trastuzumab group. The joint analysis of 
the US studies (NSABP-B31 and NCCTG-N9831) showed a 
similar hazard ratio (HR) for 12-month trastuzumab and a 
control group that did not receive this drug, with a benefit of 
disease-free survival of 11·8% at 3 years. However, in 2006 a 
smaller study (FinHer) reported just 9-week trastuzumab with 
chemotherapy versus chemotherapy control, and showed very 
similar results with a benefit in disease-free survival of 11·7% at 
3 years for 9-week trastuzumab. This result prompted a 
substantial interest in whether duration of trastuzumab could 
be reduced and a number of trials were started all with a 
non-inferiority design, to establish whether shorter duration 
trastuzumab could have similar efficacy but reduced toxicity.
Added value of this study
The Persephone trial was a pragmatic study of 6-month versus 
12-month trastuzumab, which mapped onto standard practice 
in the UK and included all patients who were planned to receive 
adjuvant or neoadjuvant trastuzumab and chemotherapy. 
Broad eligibility criteria, and in particular the inclusion of all 
chemotherapy regimens, ensured that results would be directly 
applicable to similar patients in the clinic. The trial has a 
non-inferiority design and, with recruitment of over 
4000 pa tients, was powered to test whether 6-month 
treatment was no worse than 3% less of the standard 
disease-free survival with 12-month treatment. PERSEPHONE is 
the largest of the reduced duration, adjuvant trastuzumab 
trials, it recruited the required number of patients, and accrued 
the number of events set out in the statistical analysis plan. 
This trial is the only one to show clear non-inferiority for reduced 
duration trastuzumab in HER2-positive early breast cancer.
Implications of all the available evidence
Available evidence for trastuzumab duration includes the SOLD 
and Short-HER trials, which compared 9-week trastuzumab 
with 12-month trastuzumab, and neither trial showed 
non-inferiority. The HORG trial (n=481) and the PHARE trial 
(n=3380) compared 6-month with 12-month trastuzumab 
and also did not show non-inferiority. The PHARE trial was 
presented in December, 2018, with a median follow-up of 
90 months and showed a HR of 1·08 (95% CI 0·93–1·25), which 
is remarkably similar to the data we report from PERSEPHONE’s 
findings (1·07 [0·93–1·24]). However, the PHARE trial set a 
2% non-inferiority margin and HR boundary of 1·15, and, 
therefore, accordingly cannot claim non-inferiority. During the 
trial, standard treatments gradually changed in the clinic and 
PERSEPHONE has captured these data. PERSEPHONE is the 
only trial to show clear non-inferiority for 6 months of 
trastuzumab in the early disease setting in the population 
treated and we believe this result, together with the recent, 
mature data from PHARE, should signal reduced duration 
trastuzumab becoming a standard of care in patients with 
HER2-positive early breast cancer.
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research personnel in local networks to support the trial. 
The trial was run under the auspices of an independent 
data safety and moni toring committee (IDSMC), an 
independent trial steering committee (TSC), and a trial 
management group (TMG). Ethical approval is from the 
MREC. The protocol can be found online on the Warwick 
Clinical Trial Unit website.
Participants
Eligible patients, aged 18 years or older, had a histological 
diagnosis of invasive early breast cancer with over-
expression of HER2 receptor, defined according to the 
American Society of Clinical Oncology and College of 
American Pathologists guidelines.19 All patients had a 
clear indication for chemotherapy and provided written 
informed consent. At the beginning of the trial, all 
patients were randomised before starting trastuzumab. 
However, in 2009, recruitment numbers remained 
substantially lower than expected and after discussion 
between the TMG, TSC, IDSMC, and funders, a pro tocol 
amendment (protocol version 3.1; July, 2009) allowed 
randomisation to occur at any time up to and including 
the ninth cycle of trastuzumab. All participants were 
considered medically fit to receive treatment by the 
responsible clinician. Female patients who were of child-
bearing potential were non-pregnant, non-lactating, and 
agreed to use adequate contraception during treatment. 
For full eligibility criteria see online protocol.
Randomisation and masking
The trial was open label and patients were randomly 
assigned (1:1) to either 12 months (standard 18 cycles) 
of trastuzumab or 6 months (experimental nine cycles) 
of trastuzumab (figure 1). Randomisation was done by 
telephone to the Warwick Clinical Trials Unit, where a 
central computerised minimisation procedure used the 
following stratification variables: oestrogen receptor status 
(positive or negative); chemotherapy type (anthracycline 
without taxane, anthra cycline with taxane, taxane without 
anthracycline, or neither anthracycline nor taxane); che mo-
therapy timing (adjuvant or neoadjuvant chemotherapy); 
and trastuzumab timing (concurrent or sequential).
Procedures
Trastuzumab was administered every 3 weeks either 
intravenously or, following a third protocol amendment 
(version 4.0, published Oct 31, 2013), subcutaneously. 
Switching from intravenous to subcutaneous route was 
allowed at clinician discretion. The intravenous loading 
dose was 8 mg/kg followed by maintenance doses of 
6 mg/kg, and the subcutaneous dose was fixed at 600 mg.
After randomisation, patients were followed up rou-
tinely at the centre where the patient was recruited or an 
associated institution with ethical approval for the study. 
Follow-up was every 12 weeks for the first year after 
starting trastuzumab and all toxic effects were recorded. 
Common Toxicity Criteria Adverse Events (CTCAE, 
Division of Cancer Sciences, 
Faculty of Biology, Medicine 
and Health, 
ManchesterAcademic Health 
Science Centre, University of 
Manchester, Manchester, UK 
(Prof A M Wardley)
Correspondence to: 
Prof Helena Earl, Department of 
Oncology, Addenbrooke’s 
Hospital, Cambridge CB2 0QQ, 
UK 
hme22@cam.ac.uk
See Online for appendix
For the trial protocol see 
https://warwick.ac.uk/fac/sci/
med/research/ctu/trials/cancer/
persephone/professionals
Figure 1: Trial profile
*Seven patients were found to be ineligible after randomisation (four had previous cancer or ductal carcinoma in situ treated with surgery and radiotherapy, two were 
HER2 negative, and one had primary cancer confined to the axilla). †11 patients were found to be ineligible after randomisation (seven had previous cancer or ductal 
carcinoma in situ treated with surgery and radiotherapy, one was HER2 negative, two had metastatic disease, and one had received >9 cycles of trastuzumab).
4089 patients randomly assigned
2045 assigned to 12 months (18 cycles) of 
trastuzumab*
2045 included in intention-to-treat analysis
1895 had complete trastuzumab treatment 
data sets
1 received no trastuzumab (cardiac 
toxicity)
130 received 1–9 cycles of trastuzumab
1764 received ≥10 cycles of trastuzumab
1556 received protocol-specified 
number of cycles
150 had some missing treatment data
28 lost to follow-up
61 withdrew from follow-up schedule
2044 assigned to 6 months (9 cycles) of 
trastuzumab† 
2043 included in intention-to-treat analysis
1941 had complete trastuzumab treatment 
data sets
2 received no trastuzumab 
(HER2-negative; metastatic disease)
1846 received 1–9 cycles of trastuzumab
1738 received protocol-specified 
number of cycles
93 received ≥10 cycles of trastuzumab
102 had some missing treatment data
1 excluded from analysis for being double 
randomised
29 lost to follow-up
38 withdrew from follow-up schedule
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version 3) grades were recorded for each trastuzumab 
cycle after randomisation. Originally, left ventricular 
ejection fraction (LVEF) assessments every 3 months 
for up to 12 months after starting trastuzumab were 
required for all patients. However, in June, 2013, the 
IDSMC recommended reducing LVEF monitoring to 
every 4 months, in line with new national guidelines.20 
Trastuzumab was discontinued if LVEF decreased to 
lower than 50%; LVEF was reassessed after 6 weeks 
and 12 weeks. Trastuzumab was restarted if the LVEF 
recovered; however, if treatment could not be restarted 
for 12 weeks because of persistently low LVEF, it was 
stopped permanently. Patients were followed up every 
6 months for the second year and annually thereafter, in 
accordance with standard local practice, and continued 
for 10 years.
The quality of life assessment schedule, defined by 
our group for the purposes of the trial, specifies 
assessments before starting trastuzumab, and then 3, 
6, 9, 12, 18, and 24 months later. All patients followed 
this schedule from the time they entered the trial, 
completing assessments at the same timepoints in 
their treatment. Patients who were randomised during 
their trastuzumab treatment did not have a baseline 
quality of life assessment and some also did not have 
the 3-month assessment if randomised after this 
timepoint. Questions regarding general health and the 
Euroqol 5D questionnaire 3 level (EQ-5D-3L) were 
recorded. The health economic analysis will be reported 
separately.
Outcomes
The primary endpoint was disease-free survival, which 
was calculated from the date of diagnostic biopsy to the 
date of first invasive breast cancer relapse (local or distant) 
or death, or to date of censor in patients alive and relapse-
free. The secondary endpoint of overall survival was also 
calculated from the date of diagnostic biopsy. Other 
secondary endpoints were expected incre mental cost-
effectiveness (health economic analysis), cardiac function 
as assessed by LVEF during treatment, and analysis of 
predictive factors for development of cardiac damage. 
Since randomisation could occur at any time up to and 
including the ninth cycle of trastuzumab, a prespecified 
landmark analysis was done from 6 months after the start 
of trastuzumab. The number of trastuzumab cycles 
received per patient was recorded, with route of admin-
istration and reasons for any deviation from protocol. 
LVEF measure ments were defined as low if results were 
less than 50% or reported as low without quantification of 
LVEF. Incidence of clinical cardiac dysfunction, defined 
as symptoms or signs of congestive heart failure or 
new cardiac medi cation, was recorded every 3 months 
for 12 months. A cardiologist (CP) was a member of the 
trials group and reviewed the cardiac toxicity together 
with the Chief Investigator (HME) and other members of 
the TMG.
Disease-free interval, distant disease-free interval, dis-
tant disease-free survival, invasive disease-free survival 
(including contralateral breast and second primary 
cancers, according to the STandardized definitions for 
Efficacy End Points system),21 and breast-cancer specific 
survival were also analysed post hoc.
Statistical analysis
The trial was designed to assess non-inferiority of the 
experimental group (6 months of trastuzumab), and 
the clinically acceptable non-inferiority margin for the 
6-month group was defined as being not worse than an 
absolute value of 3% below the 4-year disease-free survival 
of the standard group (12 months of trastuzumab). This 
3% non-inferiority margin was decided before the start of 
the trial following consensus from the trial development 
group together with the patient and public involvement 
group. Data from adjuvant trastuzumab trials at the 
time2–4 estimated the 4-year disease-free survival for 
patients treated with 12 months of trastuzumab to 
be 80%. Consequently, 4000 patients (2000 in each group) 
were required to show the non-inferiority of 6-month 
trastuzumab treatment with a 3% non-inferiority margin 
of the 4-year disease-free survival, and 5% one-sided 
significance and 85% statistical power. This calculation 
assumes a 4-year recruitment period, an additional 5-year 
follow-up period, and 4% of patients being lost to follow-
up. Survival curves were plotted using the Kaplan-Meier 
method and the HR between the two groups was 
estimated using a Cox’s proportional hazards model 
containing only the trial treatment effect, after assess-
ment of the proportionality of hazards using log-log plots. 
The upper limit of the HR required to show the 3% non-
inferiority was only to be calculated at the time of analysis 
and based on the disease-free survival in the 12-month 
group observed at the time of analysis. As described by 
Mauri and D’Agostino,22 if the upper limit of the 90% CI 
(the 95th percentile) of the estimated HR was less than 
the relevant 3% absolute non-inferiority limit, then the 
experimental group (6-month trastuzumab) would be 
regarded as non-inferior.
Warwick Clinical Trials Unit analysed all the data 
using SAS (version 9.4) software. The IDSMC-approved 
statistical analysis plan stated that the event-driven 
primary endpoint analysis required 500 disease-free 
survival events to have occurred. At this point, the 
relevant non-inferiority limits in terms of HR for 
3% non-inferiority in disease-free survival were calculated 
using the observed 4-year disease-free survival events 
in the standard, 12-month group. The statistical analy-
sis plan included a secondary analysis adjusting for 
stratification factors within the Cox model and also the 
presentation of treatment effect on disease-free survival 
for stratification variables and baseline prognostic 
factors using HR plots with the test for interaction or 
heterogeneity using Cochran’s Q.23 To remove the effect of 
timing of randomisation, the statistical analysis plan also 
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defined an exploratory landmark analysis for patients alive 
and disease-free 6 months after starting trastuzumab. All 
randomly assigned patients were included in all outcome 
analyses, and all patients who started trastuzumab were 
included in all safety analyses. All analyses were done on 
an intention-to-treat basis because the trial aimed to 
compare the duration of trastuzumab treatments in 
routine clinical practice. Treatment analyses were done 
for all patients with available data. PERSEPHONE is 
registered with EudraCT (number 2006–007018–39), 
International Stan dard Randomised Controlled Trial 
(number ISRCTN 52968807), and ClinicalTrials.gov 
(number NCT00712140).
Role of the funding source
The funder of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had 
full access to all the data and, along with LH and JAD, 
had final responsibility for the decision to submit for 
publication with the agreement of all the authors and 
the IDSMC.
Results
Between Oct 4, 2007, and July 31, 2015, a total of 
4089 patients were randomly assigned by 210 clinicians 
at 152 sites in the UK (figure 1). One double ran-
domisation reduced the analysis set to 4088 patients. 
18 patients were deemed ineligible after randomisation, 
mainly because of previous cancers or ductal carcinoma 
in situ treated with radiotherapy and surgery. Patient 
characteristics were similar between the two groups 
(table 1). Randomisation before starting trastuzumab 
occurred in 1786 [44%] of 4088 patients and the timings 
for those randomly assigned after the first cycle of 
trastuzumab are shown in the appendix (p 1).
The majority of patients (69%) had oestrogen receptor-
positive tumours. Among patients who received neoad-
juvant chemotherapy (n=620), the majority (553 [89%]) 
received anthracycline and taxane, 53 (9%) anthracycline 
without taxane, and 14 (2%) taxane without anthra cyc-
line; for patients who received adjuvant chemotherapy 
(n=3468), less than half received anthracycline and taxane 
12-month group 
(n=2045)
6-month group 
(n=2043)
Oestrogen receptor status*
Negative 633 (31%) 632 (31%)
Positive 1412 (69%) 1411 (69%)
Chemotherapy type*
Anthracycline-based 854 (42%) 846 (41%)
Taxane-based 200 (10%) 203 (10%)
Anthracycline-based and 
taxane-based
989 (48%) 991 (49%)
No taxane and no anthracycline 2 (<1%) 3 (<1%)
Chemotherapy timing*
Adjuvant 1737 (85%) 1731 (85%)
Neoadjuvant 308 (15%) 312 (15%)
Trastuzumab timing*
Concurrent 951 (47%) 952 (47%)
Sequential 1094 (53%) 1091 (53%)
Age at randomisation, years
Median (range) 56 (23–82) 56 (23–83)
<35 50 (2%) 45 (2%)
35–49 552 (27%) 557 (27%)
50–59 608 (30%) 656 (32%)
≥60 835 (41%) 785 (38%)
Nodal status at surgery (patients who received adjuvant therapy)
Negative 1003/1737 (58%) 1019/1731 (59%)
1–3 nodes positive 479/1737 (28%) 486/1731 (28%)
4+ nodes positive 244/1737 (14%) 211/1731 (12%)
Unknown 11/1737 (<1%) 15/1731 (<1%)
Tumour size (patients who received adjuvant therapy)†
≤2 cm 824/1737 (47%) 807/1731 (47%)
>2 and ≤5 cm 778/1737 (45%) 786/1731 (45%)
>5 cm 87/1737 (5%) 83/1731 (5%)
Unknown 48/1737 (3%) 55/1731 (3%)
(Table 1 continues in next column)
12-month group 
(n=2045)
6-month group 
(n=2043)
(Continued from previous column)
Tumour grade‡
I (well differentiated) 29 (1%) 34 (2%)
II (moderately differentiated) 628 (31%) 642 (31%)
III (poorly differentiated) 1322 (65%) 1297 (63%)
Unknown 66 (3%) 70 (3%)
Ethnicity
White 1658 (81%) 1648 (81%)
Asian 57 (3%) 52 (3%)
Black 52 (3%) 45 (2%)
Other 17 (1%) 21 (1%)
Unknown 261 (13%) 277 (14%)
Menopausal status before chemotherapy
Premenopausal 567 (28%) 580 (28%)
Perimenopausal 110 (5%) 150 (7%)
Postmenopausal 1144 (56%) 1070 (52%)
Not assessable or not available 224 (11%) 243 (12%)
Reported previous use of cardiac medication
Yes 44 (2%) 55 (3%)
No 2001 (98%) 1988 (97%)
HER2 immunohistochemistry score and FISH positivity
3+ 1460 (71%) 1487 (73%)
2+ and FISH positive 540 (26%) 497 (24%)
Not available 45 (2%) 59 (3%)
Data are n (%), unless otherwise specified. Six men are included in the 
4088 patients, four in the 12-month group and two in the 6-month group. 
FISH=fluorescence in-situ hybridisation. *Stratification variable. †Size of the largest 
invasive tumour at diagnosis. ‡Grade of the largest invasive tumour at diagnosis. 
Table 1: Baseline characteristics of trial participants
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(1427 [41%]) or anthracycline without taxane (1647 [47%]), 
and 389 (11%) received taxane without anthracycline 
(appendix p 1). UK standard practice gradually changed 
during trial recruitment with a steady increase in 
anthracycline and taxane combinations, trastuzumab 
commencing con currently with taxanes but not anthra-
cyclines, taxane-based treatment without anthracyclines, 
and neoadjuvant timing (appendix p 2). Patients given 
trastuzumab and chemo therapy concurrently com pared 
with sequentially, in the adjuvant group, were more often 
node positive (749 [53%] of 1412 patients vs 671 [33%] of 
2056, p<0·0001), had larger tumours (>2 cm; 777 [55%] 
of 1412 patients vs 957 [47%] of 2056 patients, p<0·0001); 
in the whole group, patients more often received 
neoadjuvant treatment (491 [26%] of 1903 patients vs 
129 [6%] of 2185 patients, p<0·0001) and had shorter 
median duration of follow-up (4·5 years [IQR 3·3–5·9] 
vs 5·8 years [4·5–7·4]; appendix pp 2–4). More than half 
of the patients receiving adjuvant chemotherapy were 
node negative (2022 [58%] of 3468 participants) and 
1631 [47%] of 3468 patients in this group had tumours 
smaller than 2 cm (table 1).
Complete trastuzumab administration details are 
available for 3836 (94%) of 4088 patients: 1895 (93%) of 
12-month treatment patients and 1941 (95%) of 6-month 
treatment patients (figure 1). 40 530 (82%) of 49 632 tras-
tuzumab cycles were administered intravenously and 
9102 (18%) of 49 632 cycles subcutaneously. In total, 
3294 (86%) of 3836 patients received the protocol-
specified number of trastuzumab cycles: 1556 (82%) of 
1895 pa tients assigned to 12-month treatment who had 
available treatment data and 1738 (90%) of 1941 patients 
assigned to 6-month treatment with available treatment 
data. The most common reasons for early treatment 
cessation were cardiac toxicity (146 [8%] of 1894 patients 
in the 12-month group, 61 [3%] of 1939 patients in the 
6-month group) and patient request (91 [5%] of 1894 pa-
tients in the 12-month group, 24 [1%] of 1939 patients in 
the 6-month group; figure 1). Delays occurred in 3631 (7%) 
of 49 632 cycles (appendix p 4), the main reasons being 
holidays, sepsis or infection, and cardiotoxicity. The 
most common chemotherapy treatments (known for 
3959 patients: 1985 patients in the 12-month group 
and 1974 patients in the 6-month group), were fluoro-
uracil, epirubicin, and cyclophos phamide, with docetaxel 
(811 [41%] of 1985 patients in the 12-month group vs 
790 [40%] of 1974 in the 6-month group), and without 
docetaxel (548 [28%] of 1985 vs 567 [29%] of 1974).
At database lock on April 17, 2018, with a median follow-
up of 5·4 years (IQR 3·6–6·7) for both treatment groups 
and 3588 (96%) of 3753 alive patients followed up for at 
least 2 years, 335 deaths had been reported (156 [8%] of 
2045 patients in the 12-month group and 179 [9%] of 2043 
patients in the 6-month group), the majority (272 [81%] of 
335 patients: 129 [83%] of 156 in the 12-month group and 
143 [80%] of 179 in the 6-month group) due to breast cancer 
(table 2). Local or distant relapse occurred in 452 (11%) 
of 4088 patients, with distant metastases in 373 patients 
(183 [9%] of 2045 in the 12-month group vs 190 [9%] of 
2043 patients in the 6-month group). These metastases 
occurred in the liver (81 [44%] of 183 patients vs 79 [42%] of 
190 patients), bone (61 [33%] patients vs 81 [43%] patients), 
lung (72 [39%] patients vs 67 [35%] patients), and brain 
(38 [21%] patients vs 40 [21%] patients). A relapse or death 
was reported for 512 (13%) patients overall.
The 4-year disease-free survival in the 12-month group 
was 89·8% (95% CI 88·3–91·1) and 89·4% (87·9–90·7) 
12-month 
group 
(n=2045)
6-month 
group 
(n=2043)
Death 156 (8%) 179 (9%)
Breast cancer listed as a cause 129 (6%) 143 (7%)
Breast cancer not listed as a cause, 
but a local or distant relapse reported
2 (<1%) 6 (<1%)
Breast cancer not listed as a cause and 
no local or distant relapse reported
25 (1%) 30 (1%)
Relapse* 218 (11%) 234 (11%)
Local relapse 79 (4%) 77 (4%)
Distant relapse 183 (9%) 190 (9%)
Relapse or death 247 (12%) 265 (13%)
Second primary 58 (3%) 52 (3%)
Data are n (%). *Patients can have both a local and distant relapse recorded. 
Table 2: Details of events
Figure 2: Kaplan-Meier plots of disease-free survival (A) and overall survival (B) 
for 6-month and 12-month trastuzumab treatment groups
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Figure 3: Forest plots of 
disease-free survival for all 
patients (A) and patients 
who received adjuvant 
treatment (B)
FISH=fluorescence in-situ 
hybridisation. ER=oestrogen 
receptor.
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in the 6-month group (figure 2A), showing a 0·4% 
absolute difference in disease-free survival between 
treatment groups at 4 years. Thus, with the non-
inferiority margin of 3%, the non-inferiority limit for 
the HR was set at 1·32. The HR for relapse or death 
with 6 months compared with 12 months trastuzumab 
was 1·07 (90% CI 0·93–1·24, non-inferiority p=0·011); 
this outcome met the prespecified definition of 
non-inferiority. The two-sided p value for difference 
between treatments (superiority) was 0·42. Adjustment 
for all stratification factors gave the same results with 
an HR of 1·07 (90% CI 0·93–1·24; non-inferiority 
p=0·0097). Analysis of overall survival (figure 2B) also 
met the prespecified definition of non-inferiority (4-year 
overall survival of 94·8% [95% CI 93·7–95·8] in the 
12-month group and 93·8% [92·6–94·9] in the 6-month 
group), showing a 1% absolute difference in overall 
survival between treatment groups at 4 years. The non-
inferiority limit for the HR was set at 1·60. The HR 
for overall survival was 1·14 (90% CI 0·95–1·37, 
non-inferiority p=0·0010). The two-sided p value for 
difference between treatments was 0·22 and adjustment 
for all stratification factors resulted in similar results 
(HR 1·13 [90% CI 0·94–1·35]).
Forest plots for disease-free survival that included all 
patients (figure 3A) showed heterogeneity for chemo-
therapy type (p=0·011), predominantly driven by the small 
number of events in the taxane-only group, in which 
most patients received docetaxel with cyclophosphamide.24 
The timing of trastuzumab relative to chemotherapy 
(concurrent or sequential) showed heterogeneity between 
groups (p=0·0010), favouring the 12-month treatment for 
patients receiving concurrent trastuzumab. Forest plots 
for overall survival (appendix p 7) also showed hetero-
geneity for concurrent and sequential treatments; they 
additionally showed heterogeneity for oestrogen receptor-
status (p=0·019), with improved outcomes for 12-month 
trastuzumab treatments for patients with oestrogen 
receptor-negative disease. No heterogeneity was ob served 
for age, grade, menopausal status, or HER2 score 
(immuno histochemistry score 3+, or score 2+ with fluo-
rescence in-situ hybridisation-positive) for disease-free 
survival or overall survival. Exploratory forest plots for 
patients who received adjuvant therapy only (figure 3B; 
appendix p 8) showed similar results, with no hetero-
geneity for node status, size, and combined oestrogen 
receptor and node status.
The landmark analysis of disease-free survival and 
overall survival included 4009 patients (2009 patients in 
the 12-month group and 2000 patients in the 6-month 
group) who remained alive and disease-free 6 months 
after starting trastuzumab. Kaplan-Meier (figure 4) and 
forest plots (appendix pp 9–12) for landmark disease-free 
survival and overall survival showed similar results to 
those observed for disease-free survival and overall 
survival. Landmark 4-year disease-free survival was 
88·3% for the 12-month group and 88·2% for the 
6-month group (absolute difference 0·1%). Therefore, the 
non-inferiority limit for the HR was set at 1·28 and, with 
a calculated HR of 1·07 (90% CI 0·92–1·24), this outcome 
met the prespecified definition of non-inferiority (non-
inferiority p=0·023). Landmark 4-year overall survival 
was 92·8% for the 12-month group and 92·2% for the 
6-month group (absolute difference 0·6%). Thus, the 
non-inferiority limit for the HR was set at 1·44 and, with 
a calculated HR of 1·13 (90% CI 0·94–1·37), this outcome 
met the prespecified definition of non-inferiority (non-
inferiority p=0·017). Congruent results were found for 
disease-free interval, distant disease-free interval, distant 
disease-free survival, invasive disease-free survival, and 
breast-cancer specific survival analyses (data not shown).
During the 12-month period after starting trastuzumab, 
a higher proportion of 12-month patients (459 [24%] of 
1894 patients) than 6-month patients (373 [19%] of 
1939 patients, p=0·00020) reported at least one adverse 
event of severe grade (ie, CTCAE ≥3, or CTCAE=2 for 
palpitations; table 3). The excesses were in cough 
(82 [4·3%] of 1894 patients in the 12-month group vs 44 
[2·3%] of 1939 patients in the 6-month group, p=0·00049), 
palpitations (91 [4·8%] vs 52 [2·7%], p=0·00072), fatigue 
(226 [11·9%] vs 167 [8·6%], p=0·00086), pain (98 [5·2%] vs 
62 [3·2%], p=0·0029), chills (67 [3·5%] vs 40 [2·1%], 
p=0·0075), muscle or joint pain (215 [11·4%] vs 174 [9·0%], 
p=0·017), and nausea (35 [1·9%] vs 20 [1·0%], p=0·047; 
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Figure 4: Kaplan-Meier plots of landmark analysis from 6-months after 
starting trastuzumab treatment
(A) Disease-free survival. (B) Overall survival.
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appendix p 13). These were seen predominantly during 
the 7–12-month period. Similarly, 67 serious adverse 
reactions were reported in 64 patients in the 12-month 
group and 34 events in 29 patients in the 6-month group; 
the excesses seen during the 7–12 month period. Clinical 
cardiac dysfunction was reported more commonly in the 
12-month group (224 [11%] of 1968 patients) than in the 
6-month group (155 [8%] of 1994 patients; p=0·00014; 
table 3). A small absolute difference in clinical cardiac 
dysfunction rates was observed in the first 6 months 
(p=0·018), with a larger difference during the 7–12-month 
period (p=0·00020). Trastuzumab was stopped early 
because of cardiac toxicity in 146 (8%) of 1894 patients 
in the 12-month group and 61 (3%) of 1939 patients in 
the 6-month group (p<0·0001).
In total, 19 414 measurements of LVEF were made in 
4078 patients: 10 162 in 2040 12-month patients and 
9252 in 2038 6-month patients. During the first 
6 months of treatment, proportions of patients with low 
LVEF were 7% in both groups (p=0·96). However, 
during months 7–12, this proportion increased for the 
12-month group (8%) but decreased for the 6-month 
group (5%; p=0·0003 for difference between groups). 
During months 7–12, substantial decreases of LVEF to 
less than 50% after a baseline of 59% or more occurred 
in 71 (4%) of 1873 patients in the 12-month and 32 (2%) 
of 1693 patients in the 6-month group (p=0·0010). 
11 deaths were considered cardiac (primary or contribu-
tory cause); however, none occurred during trastuzumab 
treatment and none were considered to be associated 
with trastuzumab by the TMG (appendix p 5, 6). Com-
paring the 1786 (44%) of 4088 patients randomised 
into the trial before the start of trastuzumab with 
all patients, the comparison of toxicity between the 
two treatment groups was broadly similar, although 
toxicity, including cardiotoxicity, showed marginally 
higher proportions of patients reporting these effects in 
both 6-month and 12-month treatment groups for 
patients randomised before the start of trastuzumab 
(appendix p 6).
3910 patients (1960 patients in the 12-month group, 
1950 patients in the 6-month group) participated in the 
substudy assessing quality of life. In both groups, feelings 
of general health declined during the first 3 months 
of trastuzumab (appendix p 14), when 1816 (46%) of 
3910 patients were receiving concurrent chemotherapy, 
and then steadily improved after completion of treatment. 
The EQ-5D-3L health state remained steady from baseline 
to 3 months for both randomised groups and appeared to 
slowly increase after this period, occurring slightly later 
for 12-month patients (appendix p 15).
Discussion
PERSEPHONE showed non-inferiority for 6 months of 
trastuzumab compared with 12 months. Our definition of 
non-inferiority was no worse than 3% absolute below the 
standard group’s 4-year disease-free survival, and the non-
inferiority limit was thus calculated as an HR of less 
than 1·32. Notably, the upper confidence limit of the HR 
was 1·24, which is statistically significantly below this 
non-inferiority boundary (non-inferiority p=0·011). This 
finding reflects that, although the non-inferiority boundary 
was set at 3%, the actual point estimate reduction observed 
was very small at 0·4% for 4-year disease-free survival 
and 0·1% for the landmark 4-year disease-free survival.
Other outcome analyses, including overall survival, 
landmark overall survival 6 months after the start of 
trastuzumab, and sensitivity analyses for other survival 
12-month group 6-month group
Total Months 1–6 Months 7–12 Total Months 1–6 Months 7–12
Adverse event with severe* CTCAE grade 459/1894 (24%) 350/1894 (18%) 259/1764 (15%) 373/1939 (19%) 370/1939 (19%) 8/93 (9%)
Serious adverse reaction to trastuzumab† 64/2044 (3%) 39/2044 (2%) 25/2019‡ (1%) 29/2041 (1%) 28/2041 (1%) 2/2015‡ (0·1%)
Clinical cardiac dysfunction§ 224/1968 (11%) 164/1968 (8%) 157/1936 (8%) 155/1994 (8%) 126/1994 (6%) 96/1894 (5%)
Stopped trastuzumab permanently due 
to cardiac toxicity
146/1894 (8%) 63/1894 (3%) 83/1764 (5%) 61/1939 (3%) 60/1939 (3%) 1/93 (1%)
Cardiac death¶ 7/2044 (<1%) 0/2044 0/2019‡ 4/2041 (<1%) 0/2041 0/2015‡
Cardiac death related to trastuzumab¶ 0/2044 0/2044 0/2019‡ 0/2041 0/2041 0/2015‡
Low LVEF|| 228/2040 (11%) 148/2040 (7%) 151/1938 (8%) 176/2038 (9%) 146/2038 (7%) 84/1749 (5%)
Substantial falls in LVEF
Absolute decrease of ≥10% from 
baseline to <50%
163/1959 (8%) 98/1950 (5%) 102/1873 (5%) 132/1959 (7%) 102/1954 (5%) 60/1693 (4%)
LVEF <50% after a baseline of ≥59% 108/1959 (6%) 63/1950 (3%) 71/1873 (4%) 86/1959 (4%) 70/1954 (4%) 32/1693 (2%)
Data are n/N (%). CTCAE=Common Terminology Criteria for Adverse Events. LVEF=left ventricular ejection fraction. *CTCAE grade of 3 or more, or grade of 2 for palpitations. 
†Denominators exclude the three patients known not to have received trastuzumab. ‡Denominators reduced because of either deaths or withdrawal of consent for follow-up 
within the first 6 months. §Clinical cardiac dysfunction is defined as symptoms of cardiac disease, signs of congestive heart failure, use of new medication for cardiac disease, 
or a combination of these factors. ¶11 deaths were reported to have a cardiac cause, either first cause or contributory; none occurred during the first 12 months after starting 
trastuzumab treatment; nine patients died without metastatic disease and two had metastatic disease; in all cases, trastuzumab was considered unrelated or unlikely to be 
related with the cardiac problems. ||Low LVEF was defined as ejection fraction of less than 50% or unknown ejection fraction but classified on report as not normal.
Table 3: Adverse events and cardiac monitoring over the two 6-month periods
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endpoints, were all congruent, showing the non-
inferiority of 6-months treatment. In addition, fewer 
cardiac events and other toxic effects occurred with 
6-month treatment and, therefore, the balance of risk and 
benefit favours shorter treatment. Notably, the patient 
population in PERSEPHONE, mapping onto standard 
practice in the clinic, had a substantially better profile of 
standard prognostic factors than patients treated in 
the original adjuvant trastuzumab trials.2–5 The trial 
included 69% patients with oestrogen receptor-positive 
tumours compared with 36–54% in registration studies; 
58% patients were node negative compared with 7–33%; 
and 47% had tumours of 2 cm or less compared 
with 35–40%. These standard prognostic factors are 
similar to those for patients entered into PHARE12 and 
the other non-inferiority trials.15,16 PERSEPHONE re-
cruited the number of patients specified in the statistical 
plan and with an event-driven analysis was sufficiently 
powered to meet the primary endpoint. To our knowl-
edge, PERSEPHONE is the largest trastuzumab duration 
comparison study for early breast cancer and the only 
one to show non-inferiority for the primary endpoint of 
reduced duration adjuvant trastuzumab.
Before the set-up of the trial, the PERSEPHONE TMG 
and the patient and public involvement group agreed 
that an absolute difference up to 3% for the 6-month 
treatment was considered acceptable by clinicians 
and patients. This margin is commonly used in non-
inferiority trials in oncology, including in the TAILORx 
study,26 published in 2018. Funders (which provided 
national and international peer review for the trial), 
National Research Ethics Committee, and each 
recruiting centre endorsed the view that showing this 
non-inferiority margin would be important and, if 
proven, would be potentially practice changing. In the 
PERSEPHONE statistical analysis plan, we planned to 
calculate the HR limit of non-inferiority using the 
observed 4-year disease-free survival in the standard 
group at the time of the primary endpoint analysis. This 
statistical analysis plan was approved by the IDSMC as 
most appropriate for the study.
Two other randomised studies compared treatment for 
6 months with 12 months. The HORG14 study included 
only 481 patients and used a non-inferiority margin of 
8% using dose-dense fluorouracil, epirubicin, and cyclo-
phosphamide followed by docetaxel as chemotherapy 
with 6 months or 12 months of trastuzumab 
commencing concurrently with docetaxel. This relatively 
small trial with low power did not show non-inferiority 
for 3-year disease-free survival. The PHARE trial12 
had an original recruit ment target of 7000 patients with 
a 2% non-inferiority margin. The trial included fewer 
patients than originally planned (n=3384) and reported 
an early primary endpoint of disease-free survival at 
2 years on the advice of the IDSMC. The HR non-
inferiority limit was prespecified at 1·15 on the expected 
standard group for a disease-free survival of 85% at 
2 years. The trial reported an HR of 1·28 (95% CI 
1·05–1·56; non-inferiority p=0·29) and, therefore, 
did not show non-inferiority. The longer-term results 
from PHARE27 were presented in December, 2018, after 
a median of 7·5 years and the HR was 1·08 (95% CI 
0·93–1·25; non-inferiority p=0·39) with the upper 
confidence limit still exceeding the HR limit of 1·15. 
Therefore, the conclusion remained the same: non-infe-
riority was not confirmed. Although the HR at 7·5 years 
median follow-up is remarkably similar to that measured 
in the PERSEPHONE trial, each trial is correctly reported 
according to its own prespecified statistical analysis 
plan, and hence reported conclusions are different. The 
PERSEPHONE and PHARE trials groups established a 
collaboration at the start of the trials for an individual 
patient data meta-analysis or joint analysis, which 
will provide larger numbers for exploratory subgroup 
analyses.
Long-term follow-up of patients within the 
PERSEPHONE trial is planned. The importance of 
long-term follow-ups in trials of HER2-positive breast 
cancer has been emphasised by several studies in which 
results have changed with time. The longer-term follow-
up of PHARE27 showed a reduction in the HR for disease 
recurrence or death compared with the 2-year results. 
In contrast, the FinHer study,28 which provided the 
stimulus for all the reduced duration trials, showed with 
longer follow-up28 less effect in terms of the HR for 
disease recurrence or death, which increased from 0·42 
at 3 years to 0·65 with a median follow-up of more than 
5 years. In addition, a presentation29 in 2018 from a 
combined analysis of the N9831 and NSABP B31 studies 
showed that the risk of recurrence after 5 years was 
higher in patients with oestrogen receptor-positive 
and HER2-positive breast cancer than those with oestro-
gen receptor-negative and HER2-positive disease; this 
finding is relevant for PERSEPHONE because of the 
inclusion of a high proportion of oestrogen receptor-
positive patients. Longer follow-up in the PERSEPHONE 
trial will also be particularly important because changes 
in standard treatments during the trial mean that 
for concurrent, anthracycline with taxane-based, and 
neoadjuvant treatments, the follow-up will be on 
average shorter than for those receiving sequential, 
anthracycline-based and adjuvant treatment.
Two trials tested 9 weeks concurrent treatment 
versus 12 months and neither showed non-inferiority. 
SHORTHer15 randomly assigned 1253 patients and the 
non-inferiority limit for a less than 3% margin below 
standard treatment was an HR of less than 1·29 for the 
primary endpoint of disease-free survival at 5 years; the 
trial HR was 1·15 (90% CI 0·91–1·46). SOLD16 randomly 
assigned 2176 patients and the non-inferiority limit for a 
margin of less than 4% was an HR of less than 1·385 for 
the primary endpoint of disease-free survival at 5 years; 
the trial HR was 1·39 (90% CI 1·12–1·72). One potential 
explanation is that the total dose of trastuzumab in the 
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9-week group was 20 mg/kg, which is substantially less 
than the 56 mg/kg in PERSEPHONE, PHARE,12 and 
HORG.14 This total dose might be insufficient to produce 
a non-inferior outcome compared with 12 months, even 
when used concurrently with docetaxel immediately 
after surgery.
Heterogeneities between prespecified stratification 
subgroups are seen in the PERSEPHONE trial. For 
disease-free survival, there is apparent heterogeneity 
(p=0·0010) for timing of trastuzumab and chemotherapy: 
patients receiving concurrent treatment appeared to 
benefit more from standard 12 months of trastuzumab. 
This result is intriguing because we anticipated that 
concurrent rather than sequential timing of trastuzumab 
and chemotherapy would show non-inferiority on the 
basis of evidence of synergy of concurrent treatment 
from in-vitro data,30 and metastatic1 and adjuvant7,12,31 
clinical trials. We cannot readily explain the heterogeneity 
measured in our trial for trastuzumab scheduling and 
duration, but it is important to note that the decision to 
use concurrent or sequential treatment was selected by 
investigators and not randomised. Given that patients 
treated with concurrent chemotherapy also generally 
had more high-risk features, it is not clear whether the 
observed heterogeneity is due to the treatment schedule 
itself, the type of chemotherapy used, or whether it 
reflects the underlying risk of relapse. However, 
although the trial was stratified by concurrent and 
sequential chemotherapy and subgroups are bal anced in 
terms of numbers of patients receiving either 6 or 
12 months trastuzumab, these subgroups are smaller 
and, therefore, lack statistical power. All patients in 
the concurrent group received either anthracycline 
and taxane combinations or taxane-based chemothe-
rapy without anthracyclines. HERA2,32 is the only trial 
reporting data for an exploratory subgroup analysis of a 
non-randomised comparison of sequential admin-
istration of trastuzumab after anthracycline and taxane, 
with trastuzumab after anthracycline without taxane 
chemotherapy Although trastuzumab appeared to be 
less efficacious in the anthracycline and taxane group 
than in the anthracycline alone group, this interaction 
was not found to be statistically significant. Although 
we acknowledge that any possible interaction between 
concurrent and sequential trastuzumab with chemo-
therapy might raise some concern, this subgroup 
analysis lacks statistical power for non-inferiority. 
The heterogeneity showed for different chemotherapy 
backbones is driven mainly by the taxane without 
anthracycline group and this result should be interpreted 
with caution given the small size of this group and 
the very small number of events. For overall survival in 
the PERSEPHONE trial, heterogeneity was also shown 
for oestrogen receptor status; patients with oestrogen 
receptor-negative disease appeared to benefit more from 
12 months trastuzumab, which is perhaps not surprising 
given the increased risk of relapse in this group.
PERSEPHONE mapped onto standard practice in the 
UK and study strengths are broad inclusion criteria, 
which allowed recruitment of a large number of patients 
in routine clinics and ongoing recruitment as stan-
dard chemotherapy regimens and trastuzumab timing 
changed. The limitations of this design include the 
potential for complex interactions between trastuzumab 
duration and prognostic factors, the changing standard 
practice over the 8 years of the trial, the variable timing 
of randomisation potentially introducing ascertainment 
bias, and selection of chemotherapy and trastuzumab 
timing according to perceived risk by the investigators 
(ie, concurrent preferred in high-risk patients; appendix 
pp 2–4). An additional limitation that must be considered 
is that the analyses were done according to the intention-
to-treat principle. Although we believe that this analysis 
is the most appropriate to use, ensuring unbiased 
estimates, it can potentially underestimate differences 
between treatment groups and thus drive the results 
towards non-inferiority. This limitation is a concern 
particularly when adherence to treatment is low, 
differential loss to follow-up occurs, or both. However, 
in the PERSEPHONE trial, adherence to protocol-
mandated treatment is high and loss to follow-up is low.
All reduced-duration trastuzumab trials have shown 
less cardiotoxicity for the shorter duration.11,15,16 In 
addition, the HERA trial showed that 24 months of 
trastuzumab further increased rates of cardiotoxicity 
without improving cancer outcomes.5,9 As part of the 
translational programme in PERSEPHONE, over 80% of 
patients have donated blood samples that will be part of 
a genome-wide association study of cardiotoxicity with 
investigation of interaction with duration of treatment.
Substantial changes to the management of HER2-
positive early breast cancer over the past 13 years have 
occurred, since the concept for the PERSEPHONE 
trial was developed alongside the other duration trials. 
The trial was designed to be pragmatic, map onto stan-
dard practice, which allowed patients to continue to be 
enrolled since standard chemotherapy regimens and 
trastuzumab timings changed. Although this approach 
is an advantage for trial recruit ment and ensures 
contemporaneity, one of the limitations of this design 
is that there will not be sufficient power in different 
subgroups to confirm non-inferiority. Following the report 
of N9831 in 2011,31 which showed superiority of concurrent 
trastuzumab and taxane chemotherapy over sequential 
trastuzumab, the use of concurrent treatments increased. 
Until 2011, the majority of patients in the UK received 
standard anthracycline-based regimens with sequential 
trastuzumab similar to those used successfully in HERA.2 
The docetaxel, carboplatin, and herceptin regimen from 
the BCIRG 006 study4 and the adjuvant paclitaxel and 
trastuzumab regimen33 which avoid anthracyclines, are 
now widely used in North America and are gaining 
acceptance in Europe, including the UK. The adjuvant 
paclitaxel and trastuzumab regimen was developed in 
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particular for patients with low-risk node-negative breast 
cancer and tested in a phase 2 non-randomised study.33 
Only 403 (10%) patients in our study, who were enrolled 
mostly towards the end of the recruitment period, 
received non-anthracycline containing regimens, in 
whom very few events have been reported; therefore, no 
conclusions can be drawn about the effect of a short-
duration trastuzumab treatment in combination with a 
non-anthracycline regimen.
Additional advances in the management of HER2-
positive early breast cancer warrant consideration. Trials 
of neoadjuvant therapy can provide personalised HER2-
directed therapies with potential for both escalation and 
de-escalation strategies. Use of dual anti-HER2 therapy 
(trastuzumab and pertuzumab) with chemo therapy has 
been increasing in the neoadjuvant setting following the 
Neo-SPHERE trial,34,35 which showed improved patho-
logical complete response and disease-free survival. In 
the Katherine trial,36 published in 2019, trastuzumab 
emtansine was tested against trastuzumab after the 
combination of neoadjuvant chemotherapy and anti-
HER2 therapy did not result in a pathological complete 
response. The estimated percentage of patients who 
were free of invasive disease at 3 years was 88·3% in 
the trastuzumab emtansine group and 77·0% in the 
trastuzumab group. Invasive disease-free survival was 
significantly higher in the T-DM1 group than in the 
trastuzumab group (HR for invasive disease or death 
0·50 [95% CI 0·39–0·64], p<0·001).36 This significant 
improvement in outcomes is likely to lead to an appro-
priate escalation of standard treatment in the post-
neoadjuvant setting, at least for patients who do not 
achieve pathological complete response with neoad-
juvant treatment. However, patients who do achieve a 
pathological complete response could be considered for 
trials that are planned for de-escalation of HER2 therapy. 
The APHINITY trial37 reported improved outcomes 
for the addition of 12-month adjuvant pertuzumab to 
12-month trastuzumab treatment. The reduction in 
disease recurrence was relatively small, albeit statistically 
significant (HR 0·81 [95% CI 0·66–1·00], p=0·045) and 
subgroup analysis showed a larger effect for the node-
positive subgroup. More precise prognostic or predictive 
classifications are urgently required38 so that the results 
of the de-escalation trials and those escalating treat ment 
with dual HER2 therapy37 can be appropriately applied 
to optimise effectiveness while reducing toxicity and 
containing cost. As part of the translational research 
programme within the PERSEPHONE trial, over 80% of 
patients have donated formalin-fixed paraffin-embedded 
tumour tissue and germline blood, and our aim is to 
investigate whether it is possible to personalise tras-
tuzumab duration taking into account germline and 
tumour genomics, as well as efficacy, toxicity, and 
standard prognostic factors.
In general, very substantial challenges remain to de-
escalating effective treatments that have been used as 
standard for many years. An understandable reluctance 
on the part of both oncology teams and their patients to 
consider a change to practice, which has been established 
since 2005, is expected, despite the potential benefit 
for the individual patient of reduced toxicity, length of 
treatment, and a more rapid return to normal life. We are 
convinced that the optimal approach to evaluate shorter 
durations is to use registration trials, and we would 
strongly encourage such testing for new targeted adjuvant 
cancer therapies. Although we have shown non-inferiority 
for trastuzumab in the population we tested, discussion 
and intense debate about our results is ongoing, including 
whether or not these are applicable in 2019 compared 
with 2007 when the study was designed, because of 
the changes in standard treatments for patients with 
HER2-positive breast cancer that have occurred. Duration 
questions within registration trials could only occur with 
substantial high-level international collaboration between 
the pharmaceutical industry, international academic 
groups, and governments or medicines approval bodies 
(such as the European Medicines Agency and the US 
Food and Drug Administration), with input from the 
wider cancer specialist teams and patients with cancer, 
as has been discussed by Ponde and colleagues.39 If 
shorter treatments are found to be non-inferior by agreed 
statistical criteria at the outset, then these treatments will 
become the standard of care on licensing. The escalating 
cost of effective novel anti-cancer treatments is rapidly 
becoming unsustainable even for wealthy nations, and 
we believe clinical trials designed to test the non-
inferiority of shorter treatments should become one of 
the priorities in cancer research.
In conclusion, in the PERSEPHONE trial, we have 
shown non-inferiority for 6-month adjuvant trastuzumab 
compared with 12-month treatment in patients with 
HER2-positive early breast cancer. The observed abso-
lute difference in the primary endpoint of disease-free 
survival at 4 years was only 0·4%. This result signals the 
potential of reducing treatment duration to 6 months 
and, thereby, toxicity and cost, while obtaining similar 
efficacy for at least some women with HER2-positive 
breast cancer. This trial provides a positive result and 
will stimulate substantial debate because it is the only 
reduced-duration study to show non-inferiority for shorter 
adjuvant trastuzumab treatment.
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